PBAF chromatin remodeling and small cell lung cancer
Official title: Investigating the chromatin remodeling complex PBAF in small cell lung cancer
Funded at Yale University · NIH-11368422 · Data updated 2026-11-12
This NIH grant explores how a chromatin-remodeling complex called PBAF influences the development and progression of small cell lung cancer and what this means for future therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $577,750 |
| NIH project number | 1R01CA300773-01A1 |
| Project ID | NIH-11368422 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with small cell lung cancer or those whose tumors show PBAF-related alterations may benefit from future translational findings.
✕Less likely to help
If a patient’s cancer does not involve PBAF-related pathways or chromatin remodeling, direct benefits may be limited.
What this research studies
Small cell lung cancer is a fast-growing cancer with few effective treatments. The project studies how changes in the PBAF complex affect cancer cell growth, gene expression, and chromatin structure. Researchers use patient-derived data and cellular models to understand what happens when PBAF is inactivated and how that drives tumor progression. Findings could reveal new targets for therapy and strategies to slow or stop this aggressive disease. The work is led by Yale University scientists and aims to translate mechanistic insights toward clinical applications.
Why it matters
Potential benefit: If successful, the research could identify new treatment targets and approaches for patients with small cell lung cancer.
How similar studies have gone: Previous studies in related SWI/SNF chromatin remodelers have shown that targeting these pathways can influence tumor growth, supporting the potential for benefit.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Augert, Arnaud a. — Yale University
- Study coordinator: Augert, Arnaud a.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.